Is ArriVent BioPharma, Inc. (AVBP) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 22.6% / 30% | 0.1% / 30% | N/A | ✓ HALAL |
| DJIM | 0.0% / 33% | 22.6% / 33% | 0.1% / 33% | N/A | ✓ HALAL |
| MSCI | 0.1% / 33% | 79.6% / 33% | 0.2% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 22.6% / 33% | 0.1% / 33% | N/A | ✓ HALAL |
| FTSE | 0.1% / 33% | 79.6% / 33% | 0.2% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -58.9% | |
| Return on Assets (ROA) | -36.5% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$161M |
| Free Cash Flow | -$161M |
| Total Debt | $14,000 |
| Debt-to-Equity | 0.0 |
| Current Ratio | 12.8 |
| Total Assets | $333M |
Price & Trading
| Last Close | $21.80 |
| 50-Day MA | $22.99 |
| 200-Day MA | $21.15 |
| Avg Volume | 504K |
| Beta | 1.0 |
|
52-Week Range
$15.47
| |
About ArriVent BioPharma, Inc. (AVBP)
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is ArriVent BioPharma, Inc. (AVBP) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), ArriVent BioPharma, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is ArriVent BioPharma, Inc.'s debt ratio?
ArriVent BioPharma, Inc.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.1%.
What are ArriVent BioPharma, Inc.'s key financial metrics?
ArriVent BioPharma, Inc. has a market capitalization of $947M. Return on equity stands at -58.9%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.